Zhao Y, Valdez G R, Fekete E M, Rivier J E, Vale W W, Rice K C, Weiss F, Zorrilla E P
Committee on the Neurobiology of Addictive Disorders, and Molecular and Integrative Neurosciences Department, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA.
J Pharmacol Exp Ther. 2007 Dec;323(3):846-54. doi: 10.1124/jpet.107.123208. Epub 2007 Sep 12.
The corticotropin-releasing factor (CRF) system mediates stress responses. Extrahypothalamic CRF1 receptor activation has anxiogenic-like properties, but anxiety-related functions of CRF2 receptors remain unclear. The present study determined the effects of intracerebroventricular administration of a CRF2 agonist, urocortin 3, on behavior of male Wistar rats in the shock-probe, social interaction, and defensive withdrawal tests of anxiety-like behavior. Equimolar doses of stressin1-A, a novel CRF1 agonist, were administered to separate rats. The effects of pyrazolo[1,5-a]-1,3,5-triazin-4-amine,8-[4-(bromo)-2-chlorophenyl]-N, N-bis(2-methoxyethyl)-2,7-dimethyl-(9Cl) (MJL-1-109-2), a CRF1 antagonist, on behavior in the shock-probe test also were studied. Stressin1-A increased anxiety-like behavior in the social interaction and shock-probe tests. Stressin1-A elicited behavioral activation and defensive burying at lower doses (0.04 nmol), but it increased freezing, grooming, and mounting at 25-fold higher (1-nmol) doses. Conversely, systemic administration of MJL-1-109-2 (10 mg/kg) had anxiolytic-like effects in the shock-probe test. Unlike stressin1-A or MJL-1-109-2, i.c.v. urocortin 3 infusion did not alter anxiety-like behavior in the shock-probe test across a range of doses that reduced locomotion and rearing and increased grooming. Urocortin 3 also did not decrease social interaction, but it decreased anxiety-like behavior in the defensive withdrawal test at a 2-nmol dose. Thus, i.c.v. administration of CRF1 and CRF2 agonists produced differential, but not opposite, effects on anxiety-like behavior. Urocortin 3 (i.c.v.) did not consistently decrease or increase anxiety-like behavior, the latter unlike effects seen previously after local microinjection of CRF2 agonists into the septum or raphe. With increasing CRF1 activation, however, the behavioral expression of anxiety qualitatively changes from "coping" to "noncoping" and offensive, agonistic behaviors.
促肾上腺皮质激素释放因子(CRF)系统介导应激反应。下丘脑外CRF1受体激活具有类焦虑特性,但CRF2受体与焦虑相关的功能仍不清楚。本研究确定了脑室内注射CRF2激动剂urocortin 3对雄性Wistar大鼠在焦虑样行为的电击探针、社交互动和防御性退缩试验中的行为影响。将等摩尔剂量的新型CRF1激动剂stressin1-A给予另一组大鼠。还研究了CRF1拮抗剂吡唑并[1,5-a]-1,3,5-三嗪-4-胺,8-[4-(溴)-2-氯苯基]-N,N-双(2-甲氧基乙基)-2,7-二甲基-(9Cl)(MJL-1-109-2)对电击探针试验行为的影响。stressin1-A在社交互动和电击探针试验中增加了焦虑样行为。stressin1-A在较低剂量(0.04 nmol)时引起行为激活和防御性掩埋,但在高25倍(1 nmol)的剂量下增加了僵住、理毛和骑跨行为。相反,全身注射MJL-1-109-2(10 mg/kg)在电击探针试验中具有类抗焦虑作用。与stressin1-A或MJL-1-109-2不同,脑室内注射urocortin 3在一系列降低运动和站立并增加理毛的剂量范围内,并未改变电击探针试验中的焦虑样行为。urocortin 3也没有减少社交互动,但在2 nmol剂量下可降低防御性退缩试验中的焦虑样行为。因此,脑室内注射CRF1和CRF2激动剂对焦虑样行为产生了不同但并非相反的影响。脑室内注射urocortin 3并未持续减少或增加焦虑样行为,后者与先前将CRF2激动剂局部微量注射到隔区或中缝后所见的效果不同。然而,随着CRF1激活增加,焦虑的行为表现从“应对”定性地转变为“非应对”以及攻击性、争斗性行为。